Mechanisms of p53-mediated intrinsic and extrinsic tumor suppression [PDF]
, 2014 p53 is a promising target for cancer therapy. However, the molecular basis of the p53 tumor suppression function remains incompletely understood.
Li, Hai
core +1 more source
Scientific Reports, 2018 The tumor suppressor p53 is commonly inactivated in human tumors, allowing evasion of p53-dependent apoptosis and tumor progression. The small molecule APR-246 (PRIMA-1Met) can reactive mutant p53 in tumor cells and trigger cell death by apoptosis.
Lena Haffo +7 more
doaj +1 more source
Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes. [PDF]
, 2017 Functional reactivation of p53 pathway, although arduous, can potentially provide a broad-based strategy for cancer therapy owing to frequent p53 inactivation in human cancer.
Győrffy, Balázs +7 more
core +1 more source
PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation [PDF]
, 2018 Telomeric crisis is the final replicative barrier to cell immortalisation; it is characterised by genome instability and cell death and is triggered when telomeres become critically short and are subjected to fusion. Pre-cancerous lesions, or early stage
Argani +60 more
core +3 more sources
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. [PDF]
Cancers (Basel), 2017 p53 protects cells from genetic assaults by triggering cell-cycle arrest and apoptosis. Inactivation of p53 pathway is found in the vast majority of human cancers often due to somatic missense mutations in TP53 or to an excessive degradation of the protein.
Perdrix A +6 more
europepmc +6 more sources
Die Interaktion zwischen p53 und p73 als molekulare Zielstruktur in der Tumortherapie [PDF]
, 2018 TP53 ist das in humanen Malignomen am häufigsten mutierte Tumorsuppressorgen (Kandoth et al. 2013). Mutationen des TP53-Gens führen meistens zur Expression von mutierten p53-Proteinen voller Länge, die neben einem Funktionsverlust durch onkogenes ...
Müller, Maximilian +1 more
core +1 more source
Cancer Research, 2021 Abstract Background: Cancer is among the leading causes of death worldwide. Hence, new drugs and faster screening models are needed. However, costly experiments for determining the therapeutic efficacy of drugs in animals before they reach clinical trials make the process difficult.
Sanjib Nilam Banerjee +8 more
openaire +1 more source
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness [PDF]
, 2016 Since its discovery nearly 40 years ago, p53 has ascended to the forefront of investigated genes and proteins across diverse research disciplines and is recognized most exclusively for its role in cancer as a tumor suppressor.
Mayo, Lindsey D., Olivos III, David J.
core +3 more sources
Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies [PDF]
, 2021 The cystine/glutamate antiporter xCT is a tumor-associated antigen that has been newly identified in many cancer types. By participating in glutathione biosynthesis, xCT protects cancer cells from oxidative stress conditions and ferroptosis, and ...
Barutello, G. +7 more
core +1 more source
HemaSphere, Volume 10, Issue 3, March 2026.Abstract TP53 mutations are found in over 50% of tumor types, including myeloproliferative neoplasms (MPNs). MPNs are characterized by a chronic phase, which may progress to secondary acute myeloid leukemia (sAML). Here, we discuss the physiological functions of p53 in hematopoiesis and its deregulation in MPNs.
Suzana da Silva‐Benedito +6 more
wiley +1 more source